Increased DNA methylation in the HoxA5 promoter region correlates with decreased expression of the gene during tumor promotion

Molecular Carcinogenesis
Rebecca E WatsonJay I Goodman

Abstract

Promoter-region DNA methylation inhibits transcription. A two-stage SENCAR (sensitive to mouse carcinogenesis) mouse skin carcinogenicity model was used to examine gene-specific changes in methylation during skin tumor promotion. Analysis was performed on 7,12-dimethylbenz[a]anthracene (DMBA)-initiated skin promoted with 9, 18, 27, or 36 mg cigarette smoke condensate (CSC) for 9 wk, or 27 mg CSC for 9 wk and sacrificed 6 wk afterwards (recovery group). Additionally, tumors arising following promotion with 27 mg CSC for 29 wk were assessed. Gene array analysis identified differentially expressed genes. Expression of HoxA5, a tumor suppressor gene, was decreased following 9 wk of treatment with 27 mg CSC, and returned to control levels during recovery. HoxA5 promoter methylation was measured with the enzymatic regional methylation assay (ERMA). DNA was bisulfite-modified, PCR-amplified with primers containing dam sites, incubated with [14C-methyl] S-adenosyl-L-methionine (SAM) and dam methyltransferase for DNA quantification, then incubated with [3H-methyl] SAM and SssI methylase to quantify methylation status. Higher 3H/14C ratios indicate increased methylation. The 3H/14C ratios of animals promoted with 27 or 36 mg CSC (48.2 +/...Continue Reading

References

Jan 1, 1992·Pharmacology & Therapeutics·J DiGiovanni
Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M FrommerC L Paul
Nov 1, 1986·Journal of the American Academy of Dermatology·S H Yuspa
Jul 20, 1987·Journal of Molecular Biology·M Gardiner-Garden, M Frommer
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·F Antequera, A Bird
Jan 1, 1994·Drug Metabolism Reviews·H C Pitot, Y P Dragan
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
May 1, 1997·Molecular Medicine Today·P W Laird
Aug 1, 1997·Trends in Genetics : TIG·J A YoderT H Bestor
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·S A BelinskyJ G Herman
Feb 13, 1999·Nature Genetics·P A Jones, P W Laird
May 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·S RamchandaniM Szyf
Oct 16, 1999·Science·A P Wolffe, M A Matzke
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·G J NuovoJ G Herman
Apr 11, 2001·Toxicological Sciences : an Official Journal of the Society of Toxicology·G M HellmannD J Doolittle
Jun 26, 2001·Journal of Cellular Physiology·C CilloE Boncinelli
Nov 24, 2001·Toxicological Sciences : an Official Journal of the Society of Toxicology·J I Goodman
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Jay I Goodman, Rebecca E Watson
Apr 10, 2002·Molecular and Cellular Biology·Michela CurradiNicoletta Landsberger
Aug 3, 2002·Oncogene·Melanie Ehrlich
Mar 5, 2003·Journal of Cellular Biochemistry·Melanie Ehrlich
May 30, 2003·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ammie N Carnell, Jay I Goodman
Jul 29, 2003·Toxicological Sciences : an Official Journal of the Society of Toxicology·Rebecca E WatsonJay I Goodman
Sep 26, 2003·The American Journal of Pathology·Sun LeeGyeong Hoon Kang

❮ Previous
Next ❯

Citations

Sep 18, 2010·Pathology International·Koo Han YooSung-Goo Chang
Jul 25, 2018·Journal of Cellular and Molecular Medicine·Qiuyu LinChenghe Lin
Mar 30, 2006·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ammie N BachmanJay I Goodman
Dec 28, 2019·Current Pharmaceutical Biotechnology·Konrad DziobekDariusz Boroń
Mar 25, 2016·Journal of Developmental Biology·Lucie JeannotteKim Landry-Truchon
Oct 18, 2005·Molecular Cancer Therapeutics·Curtis BalchKenneth P Nephew

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.